2022³â Á¦73Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2022-04-20±³À°ÀÏÀÚ : 2022-04-20
±³À°Àå¼Ò : ±×·£µå ÇöóÀÚ Ã»ÁÖ È£ÅÚ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2022³â Á¦73Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ´ëÇÑÇǺΰúÇÐȸ
¿¬¶ôó : 02-3473-0284
À̸ÞÀÏ :
kda@derma.or.kr ±³À°Á¾·ù : ÇǺΰú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 5Á¡ / Çʼö 1Á¡)
Áö¿ª :
Ãæû³²µµ±³À°½Ã°£ : 20 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 500,000¿ø
ºñ°í ¿ÀÇÁ¶óÀÎ Á¤È¸¿ø 70,000 ÁØȸ¿ø 30,000 / ¿Â¶óÀÎ Á¤È¸¿ø 50,000 ÁØȸ¿ø20,000 ¸¸65¼¼ ÀÌ»ó ¸éÁ¦ / ºñȸ¿ø 500,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 13:10~13:30 From university to venture ÀÌÁõÈÆ(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 14:00~14:05 Introduction Chair()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 14:05~14:50 ÀÚº»ÁÖÀÇ¿Í ÅõÀÚ ¹Ú¼¼ÀÍ(ü½½¸®ÀÚ¹®)
Åä·Ð 04-20 ±×·£µåº¼·ëAB 14:50~15:00 Q&A ()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 10:30~10:47 New horizon of wound healing ½ÅÁ¤¿ì(Â÷ÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 10:47~11:04 Acute wound management: minimization of scarring ½ÅÁ¤¿ø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 11:04~11:21 Chronic wound: how to treat ±èÈƼö(ºÎ»êÀÇ´ë)
Åä·Ð 04-20 ±×·£µåº¼·ëC 11:21~11:30 Q&A ()
±³À°½Ã°£ 04-20 Á÷ÁöȦ 14:00~14:50 Let¡¯s study health care big data analyses ¹èÁ¤¹Î(ÈúÇϿ콺ÇǺΰú)
Åä·Ð 04-20 Á÷ÁöȦ 14:50~15:00 Q&A ()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 14:00~14:05 Overview Chair()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 14:05~14:20 Mast cell and urticaria: how mast cell induces urticaria ÃÖÁ¾¿ø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 14:20~14:35 Targeting extracellular mediators for urticaria treatment (biologics) È«Á¾¼ö(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 14:35~14:50 Targeting receptors and intracellular signaling (small molecule inhibitors) ¼Çö¹Î(ÇѾçÀÇ´ë)
Åä·Ð 04-20 ±×·£µåº¼·ëC 14:50~15:00 Q&A ()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 15:30~15:35 Overview ¼Õ»ó¿í(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 15:35~15:50 New insights into AD in children °íÇöâ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 15:50~16:05 What¡¯s the difference between children¡¯s AD and adults¡¯ AD? ÀüÁöÇö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 16:05~16:20 Recent advances on the treatment of AD in children ³ªÂùÈ£(Á¶¼±ÀÇ´ë)
Åä·Ð 04-20 ±×·£µåº¼·ëC 16:20~16:30 Q&A ()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 16:30~16:35 Overview Chair()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 16:35~16:50 Best practices in treating psoriasis in sensitive areas º¯Áö¿¬(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 16:50~17:05 Assessing and managing comorbidities associated with psoriasis ±èÁ¤Àº(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 17:05~17:20 Treatment in patients with biologic failure ÃÖÀ¯¼º(¿ï»êÀÇ´ë)
Åä·Ð 04-20 ±×·£µåº¼·ëC 17:20~17:30 Q&A ()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 09:30~09:42 Á¶Á÷ °Ë»ç, ¸é¿ªÇü±¤°Ë»ç ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 09:42~09:54 Áø±Õ È«Á¾¼ö(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 09:54~10:06 ±¤°Ë»ç ¹éÀ¯»ó(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:06~10:18 øÆ÷°Ë»ç ±èÁ¤Àº(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:18~10:30 ´õ¸ð½ºÄÚÇÇ°Ë»ç ½Å±âÇõ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:30~10:42 ½ºÅ×·ÎÀ̵å À̽ÃÇü(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:42~10:54 Ç×Áø±ÕÁ¦/Ç×»ýÁ¦ ¼Çö¹Î(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 10:54~11:06 ¸é¿ª¾ïÁ¦Á¦ Á¤º¸¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 11:06~11:18 ·¹Æ¼³ëÀÌµå ±èűÕ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 11:18~11:30 Ç×È÷½ºÅ¸¹ÎÁ¦ ±Ç¼øÈ¿(°æÈñÀÇ´ë)
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 09:30~09:35 Introduction Chair()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëC 09:35~10:20 ½É»çÀÚ¿Í ÆíÁýÀÎÀ» À§ÇÑ ¿¬±¸ÃâÆÇÀ±¸® À¯ ¿µ(°í·ÁÀÇ´ë ¼Ò¾Æû¼Ò³â°ú/ÀÇÆíÇù ÃâÆÇÀ±¸®À§¿øÀå)
Åä·Ð 04-20 ±×·£µåº¼·ëC 10:20~10:30 Q&A ()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 15:30~16:20 ¼Ò¾Æ¿¡¼ ÈçÇÑ ÇǺÎÁúȯÀÇ Áø´Ü°ú Ä¡·á ±è±ÔÇÑ(¼¿ïÀÇ´ë)
Åä·Ð 04-20 ±×·£µåº¼·ëAB 16:20~16:30 Q&A ()
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 15:30~15:55 Postnatal epigenetic regulation of dermal fibroblast maturation ±Ç¿À»ó(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 15:55~16:20 The role of profilin-1 in the pathogenesis of psoriasis ±èµ¿Çö(Â÷ÀÇ´ë)
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 16:20~16:45 CRTC3, a sensor and key regulator for melanogenesis À强Àº(¿ï»êÀÇ´ë)
Åä·Ð 04-20 ¿ì¾ÏȦ 16:45~17:00 Q&A ()
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 09:30~09:35 Overview Chair()
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 09:35~09:50 Laser safe use guidance - laser hazard classification ³ªÁ¤ÀÓ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 09:50~10:05 Avoid unwanted laser complications - case review ±èÇý¼º(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 10:05~10:20 Protect yourself from virus: recommendations for cutaneous laser during COVID-19 pandemic ±Ç¼øÈ¿(°æÈñÀÇ´ë)
Åä·Ð 04-20 ¿ì¾ÏȦ 10:20~10:30 Q&A ()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 13:30~13:35 Introduction Chair()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 13:35~13:55 Quantitative and qualitative assessment of chronic pruritus Àå¿ëÇö(°æºÏÀÇ´ë)
Åä·Ð 04-20 ±×·£µåº¼·ëAB 13:55~14:00 Q&A ()
±³À°½Ã°£ 04-20 Á÷ÁöȦ 13:30~13:35 Introduction Chair()
±³À°½Ã°£ 04-20 Á÷ÁöȦ 13:35~13:55 The spatially resolved transcriptome profile of cutaneous CD30 positive lymphoproliferative disorder ÀÌ¿ìÁø(¿ï»êÀÇ´ë)
Åä·Ð 04-20 Á÷ÁöȦ 13:55~14:00 Q&A ()
±³À°½Ã°£ 04-20 Á÷ÁöȦ 17:00~17:04 Introduction Chair()
±³À°½Ã°£ 04-20 Á÷ÁöȦ 17:04~17:21 Inflammatory disease on head and neck ¿À»óÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 04-20 Á÷ÁöȦ 17:21~17:38 Benign tumors on head and neck ¹ÚÁöÇý(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 04-20 Á÷ÁöȦ 17:38~17:55 Malignant tumors on head and neck À±¼÷Á¤(Àü³²ÀÇ´ë)
Åä·Ð 04-20 Á÷ÁöȦ 17:55~18:00 Q&A ()
±³À°½Ã°£ 04-20 Á÷ÁöȦ 15:30~15:55 Atrophic acne scar treatment: practical tips À̵µ¿µ(¸®´õ½ºÇǺΰú °Ç´ëÁ¡)
±³À°½Ã°£ 04-20 Á÷ÁöȦ 15:55~16:20 Skills not to be missed: filler (filler, just remember this) ³ëÈ¿Áø(³ªÀǹ̷¡ÇǺΰú)
±³À°½Ã°£ 04-20 Á÷ÁöȦ 16:20~16:45 Skincare tips in acne patients ³ë¼º¹Î(¿¬¼¼ÆĽºÅÚÇǺΰú)
Åä·Ð 04-20 Á÷ÁöȦ 16:45~17:00 Q&A ()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 16:30~17:20 ÀÇ·áºÐÀï»ç·Ê ·ù¿µ¿í(°è¸íÀÇ´ë)
Åä·Ð 04-20 ±×·£µåº¼·ëAB 17:20~17:30 Q&A ()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 11:30~11:33 Introduction Chair()
±³À°½Ã°£ 04-20 ±×·£µåº¼·ëAB 11:33~12:00 Real world clinical experiences of dupilumab in pediatric AD patients Elaine Siegfried(Saint Louis University USA)
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 10:30~10:33 Introduction Chair()
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 10:33~11:18 Onychomycosis treatment update Á¤ÇýÁ¤(±¹¸³Áß¾ÓÀÇ·á¿ø)
Åä·Ð 04-20 ¿ì¾ÏȦ 11:18~11:30 Q&A ()
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 14:00~14:50 Why do we need to consider early intervention in psoriatic disease? ±èűÕ(¿¬¼¼ÀÇ´ë)
Åä·Ð 04-20 ¿ì¾ÏȦ 14:50~15:00 Q&A ()
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 17:00~17:25 Evolving treatments for moderate to severe atopic dermatitis °íÇöâ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 04-20 ¿ì¾ÏȦ 17:25~17:50 Real life experience of baricitinib in patients with moderate to severe atopic dermatitis ¾ÈÁö¿µ(±¹¸³Áß¾ÓÀÇ·á¿ø)
Åä·Ð 04-20 ¿ì¾ÏȦ 17:50~18:00 Q&A ()